We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Bionovo, Inc. released new data on the Company's lead drug candidate, MF101, for the treatment of vasomotor symptoms, such as hot flashes and night sweats, associated with menopause at the American Society for Mass Spectroscopy 54th Annual Meeting in Seattle.
Scios, a division of Johnson & Johnson (J&J), has announced plans to launch a large-scale international study, involving upwards of 7,000 patients, to further assess the benefits and safety profile of its cardiovascular drug Natrecor in people with acutely decompensated heart failure (DHF).
Swiss drugmaker Novartis and Canadian firm Cytopia have entered into a global license and research and development collaboration to develop orally active, small molecule therapeutics targeting JAK3 kinase for the prevention of transplant rejection and the treatment of multiple indications in autoimmune diseases such as rheumatoid arthritis, the companies announced.
The world's first medicine derived from a genetically engineered animal has been recommended for approval by a panel of European experts, following a re-examination of the evidence.
Dendrite International, Inc., a leading provider of pharmaceutical industry solutions, today announced a comprehensive three-year agreement to provide SINE Pharmaceutical Company Co., Ltd, a subsidiary of Shanghai Pharmaceutical Group Co., Ltd (SPGC) and pioneer in China's growing pharmaceutical market, with components of Dendrite's Sales Solutions.
Drug manufacturer Patheon Inc. reported lower second quarter profits but higher revenues Friday and said it plans an efficiency drive to cut costs and improve the company's bottom line.